Which is why he believes they will go down as Elon's greatest-ever invention… his biggest ever disruption.
On July 22, Elon is expected to share this new venture with the world.
Once he does, this is going to be everywhere — from Fox Business to your family's group chat.
Adams believes investors who get positioned before that date could walk away wealthier than they ever thought possible. Everyone else will be reading about it after the stocks have already run.
He'll show you exactly what Elon is building, what's inside these strange white crates… and I'll give you the name and ticker of one of his top picks to play it — completely free.
Adam O'Dell
Chief Investment Strategist, Money & Markets
Today’s editorial pick for you
AbbVie Q1 2026 Earnings: Skyrizi and Rinvoq Drive Record Growth
Posted On May 01, 2026 by Chris Markoch
AbbVie (NYSE: ABBV) delivered a powerful start to 2026, reporting first-quarter net revenues of $15.0 billion. That’s a 12.4% year-over-year increase that beat consensus estimates by roughly $300 million. Adjusted diluted earnings per share came in at $2.65, a 7.7% improvement over the prior-year period and $0.07 above the guidance midpoint, underscoring management’s consistent track record of conservative guidance and upside delivery. On a constant-currency operational basis, revenues grew 10.3%, demonstrating that the beat was driven by genuine business momentum rather than favorable foreign exchange tailwinds.
Table of Contents
The results mark yet another milestone in AbbVie’s post-Humira transformation. Just three years removed from the January 2023 loss of U.S. exclusivity on what was once the world’s best-selling drug, the company has executed one of the most successful franchise transitions in modern pharmaceutical history. Immunology revenues alone reached $7.3 billion — nearly three times Humira’s remaining global contribution — while the neuroscience segment surged 26% to $2.9 billion, reflecting the growing breadth of AbbVie’s growth platform.
Management raised full-year 2026 adjusted EPS guidance to a range of $14.08–$14.28, up from the prior range of $13.96–$14.16, and lifted full-year revenue guidance to approximately $67.3 billion, implying roughly 10% top-line growth for the full year. For investors watching ABBV, the message from Q1 is unambiguous: the diversified growth engine is firing.
Immunology and Neuroscience Power the Beat
The immunology portfolio remains AbbVie’s defining growth engine, and Q1 2026 results reinforced that thesis with authority. Global Skyrizi revenues reached $4.483 billion, up 30.9% on a reported basis and 29.2% operationally, as the drug continues to expand across its approved indications in plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Rinvoq added $2.119 billion in revenues, growing 23.3% reported and 20.2% operationally, as prescriptions in atopic dermatitis, rheumatoid arthritis, and other inflammatory indications accelerated. Together, Skyrizi and Rinvoq generated more than $6.6 billion in a single quarter — a run rate that has already surpassed AbbVie’s own long-term 2027 combined guidance target issued just a few years ago.
Humira, now firmly in managed decline, contributed $688 million globally — a 38.6% reported decrease — but that erosion was entirely expected and is increasingly immaterial relative to the scale of its successors. The immunology segment’s adjusted operating margin held firm, reflecting AbbVie’s pricing discipline and mix shift toward higher-margin next-generation therapies.
Neuroscience delivered arguably the quarter’s most impressive segment result: $2.875 billion in revenues, up 26.0% reported. Botox Therapeutic crossed $1 billion for the quarter for the first time, growing 16.5%. The migraine franchise saw explosive growth, with Qulipta up 53.6% and Ubrelvy up 41.4%. Vraylar contributed $905 million, up 18.4%, continuing its steady expansion in bipolar depression and schizophrenia.
Pipeline and Strategic Investments Add Long-Term Optionality
Beyond the headline numbers, AbbVie used Q1 to materially advance its pipeline and signal confidence in long-term manufacturing capacity. The company submitted a supplemental FDA application for Skyrizi subcutaneous induction in Crohn’s disease — a potential label expansion that would offer a more convenient dosing option supported by the positive Phase 3 AFFIRM data, with an approval decision expected later this year. Separately, AbbVie filed for a new Rinvoq indication in severe alopecia areata, backed by the Phase 3 UP-AA program, further extending the drug’s addressable market.
In oncology, the FDA approved the Venclexta plus acalabrutinib combination as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia — a clinically and commercially significant milestone. Early-stage pipeline also gained attention: ABBV-295, a non-incretin obesity candidate, showed clinically meaningful weight reduction at week 12 in a Phase 1 multiple ascending dose study, with a favorable tolerability profile.
While still early, obesity represents a potentially enormous long-term opportunity. On the manufacturing front, AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical campus in Durham, North Carolina, alongside $380 million in new API facilities in North Chicago — investments in AI-integrated production that position the company to scale its immunology and neuroscience franchises well into the next decade.
Technical Analysis: Post-Earnings Rally Faces a Critical Test
ABBV closed May 1, 2026, at $211.32, up 3.64% on the session following the earnings beat, with volume registering 10.32 million shares — elevated relative to recent averages. The daily candlestick chart shows the stock rebounding sharply from an April low near $188, recovering toward the 50-day SMA, which is declining and currently sits at $214.89 — just above the current price. This places ABBV in a technically critical zone: the post-earnings pop brings the price back to a meaningful resistance level, but the stock has not yet reclaimed the 50-day SMA.
The broader trend since the October 2025 high near $247 has been a series of lower highs and periodic tests of support, with the $210 horizontal zone — visible as a dotted support line on the chart — acting as a key battleground. A sustained close above the 50-day SMA at $214.89 would be a constructive signal. Failure to hold $210 on any pullback, however, would re-expose the $195–$200 range. The $312 long-term SMA represents a significantly longer-term technical level that underscores just how far the stock has compressed from peak valuations, and a sustained fundamental re-rating would be required to reclaim that territory.
Risks to Growth
Despite the strong Q1 print, investors should monitor several meaningful headwinds. Humira erosion, while managed, is expected to continue with global revenues guided toward $2.9 billion for full-year 2026. That was roughly half of its pre-biosimilar contribution. In aesthetics, Juvederm declined 2.9% operationally as macroeconomic pressures weigh on discretionary spending in key dermal filler markets, and category growth is expected to remain challenged in the near term.
The FDA issued a Complete Response Letter for trenibotE on manufacturing grounds, delaying what could have been a meaningful catalyst for aesthetics into 2027. Imbruvica continues its structural decline, down 24.7% in Q1, as competitive erosion in the CLL market intensifies. Lastly, the FDA’s selection of Botox Therapeutic for Medicare price negotiation in 2028 introduces a longer-dated pricing overhang on one of AbbVie’s most durable revenue streams. Large IPR&D charges ($744 million in Q1 alone) also create noise around GAAP earnings and could recur with future pipeline investments.
AbbVie’s Q1 2026 results confirm that its post-Humira growth platform is accelerating. Skyrizi and Rinvoq are growing well ahead of original guidance targets, neuroscience is emerging as a genuine second growth pillar, and management’s decision to raise full-year guidance reflects earned confidence rather than promotional optimism.
The stock’s 3.64% earnings-day gain brings ABBV back toward a decisive technical level: the declining 50-day SMA at $214.89. A sustained reclaim of that average, along with continued execution in immunology and neuroscience, would set the stage for a broader re-rating. The $312 long-term SMA remains a distant but important benchmark. That level signals the degree of multiple compression since peak Humira-era valuations, as well as the magnitude of the re-rating opportunity if AbbVie continues to deliver. Until then, $210–$215 is the zone to watch.
Tidak ada komentar:
Posting Komentar